Safety of @entity3076 in Indian XXXX - Multicentric registry of 1000 cases.

@entity1 @entity3076 @entity64 @entity548 @entity1397 @entity5771 @entity715
BACKGROUND: @entity1397 has been the only available antiplatelet drug used along with aspirin in @entity1 of ACS. In recent years 2 new antiplatelet drugs ( @entity3076 and Ticagrelor) have become available. @entity3076 in the dose of 10  mg @entity5771 has been found to be more efficacious but with increased risk of major @entity548 . For this reason it has not gained widespread usage in ACS @entity1 undergoing PCI. There are no systematic data on the use of @entity3076 in Indian population. METHOD: This is a prospective, multicentric, hospital registry of 1000 @entity1 with ACS undergoing PCI who were administered @entity3076 . The primary safety endpoint of this study was major and minor @entity548 while the efficacy endpoint is the composite of CV death, nonfatal MI, @entity64 up to 30 days after PCI. @entity1 with high @entity548 risk were excluded. RESULTS: Most @entity1 (91%) received loading dose of @entity3076 along with the maintenance dose getting according to the defined protocol. @entity1 were followed up to 30 days post procedure. Primary efficacy end point was reached in 3 @entity1 only with two of them dying due to possible stent @entity715 and the third requiring revascularization of the target vessel for stent @entity715 . One major and 19 minor @entity548 complications were recorded, with access site @entity548 in 0.7% _ non-access site @entity548 in 1.2% of the subjects. CONCLUSION: @entity3076 was found to be effective _ not associated with a high incidence of @entity548 in the high risk ACS @entity1 when those at a high @entity548 risk were excluded.
